| ID Source | ID |
|---|---|
| PubMed CID | 123827 |
| MeSH ID | M0072099 |
| Synonym |
|---|
| 63347-65-9 |
| MOLI000623 |
| technetium tc 99m edhp |
| tc-99m-fe(ii)-hedp |
| tc-99m-cu(1)-ehdp |
| tc-ethane-1-hydroxyl-1,1-diphosphonate |
| tc-99m-ehdp |
| technetium hedp |
| tc-99m-hedp |
| tc-sodium etidronate |
| technetium hydroxyethylidine diphosphonate |
| tc-99m-sn(ii)-hedp |
| technetium tc 99m etidronate |
| technetium osteoscan |
| phosphonic acid, (1-hydroxyethylidene)bis-, technetium-(99)tc salt |
| technetium tc 99m hedp |
| technetium tc 99m cuprous etidronate |
| technetium tc-99m etidronate |
| unii-13w7dmi45x |
| 13w7dmi45x , |
| technetium tc 99m etidronate [usp impurity] |
| Q27251546 |
| (1-hydroxy-1-phosphonoethyl)phosphonic acid;technetium-99 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 76 (85.39) | 18.7374 |
| 1990's | 9 (10.11) | 18.2507 |
| 2000's | 2 (2.25) | 29.6817 |
| 2010's | 1 (1.12) | 24.3611 |
| 2020's | 1 (1.12) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (9.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (3.13%) | 5.53% |
| Reviews | 3 (3.13%) | 6.00% |
| Case Studies | 14 (14.58%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 76 (79.17%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents. | 1.96 | 1 | 0 | sulfoxide; volatile organic compound | alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger |
| dithionite Dithionite: Dithionite. The dithionous acid ion and its salts. | 1.96 | 1 | 0 | sulfur oxide; sulfur oxoanion | |
| sulfites Sulfites: Inorganic salts of sulfurous acid.. sulfites : Any sulfurous acid derivative that is a salt or an ester of sulfurous acid.. organosulfonate oxoanion : An organic anion obtained by deprotonation of the sufonate group(s) of any organosulfonic acid.. sulfite : A sulfur oxoanion that is the conjugate base of hydrogen sulfite (H2SO3). | 1.96 | 1 | 0 | divalent inorganic anion; sulfur oxide; sulfur oxoanion | |
| vanilmandelic acid Vanilmandelic Acid: A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE.. vanillylmandelic acid : An aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid. | 1.96 | 1 | 0 | 2-hydroxy monocarboxylic acid; aromatic ether; phenols | human metabolite |
| homovanillic acid Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite. | 1.96 | 1 | 0 | guaiacols; monocarboxylic acid | human metabolite; mouse metabolite |
| pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium. | 2.36 | 2 | 0 | pentacarboxylic acid | copper chelator |
| etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces. | 9.66 | 89 | 2 | 1,1-bis(phosphonic acid) | antineoplastic agent; bone density conservation agent; chelator |
| hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group. | 2.37 | 2 | 0 | 4-hydroxyproline; L-alpha-amino acid zwitterion | human metabolite; mouse metabolite; plant metabolite |
| edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive. | 1.96 | 1 | 0 | ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid | anticoagulant; antidote; chelator; copper chelator; geroprotector |
| methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone. | 1.96 | 1 | 0 | 6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic |
| copper gluconate Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters. | 2.88 | 4 | 0 | organic molecular entity | |
| molybdenum Molybdenum: A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.95. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase. | 1.96 | 1 | 0 | chromium group element atom | micronutrient |
| technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years. | 7 | 76 | 1 | manganese group element atom | |
| titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures. | 1.96 | 1 | 0 | titanium group element atom | |
| erbium Erbium: Erbium. An element of the rare earth family of metals. It has the atomic symbol Er, atomic number 68, and atomic weight 167.26. | 1.95 | 1 | 0 | f-block element atom; lanthanoid atom | |
| calcium phosphate, dibasic, anhydrous calcium phosphate, dibasic, anhydrous: molecular formula CaHPO(4), DCPA=dicalcium phosphate anhydrous; don't confuse with dichloropropionanilide which also is called DCPA; MW=136.06; has greater surface area and lower pH than DCPD (dicalcium phosphate dihydrate); occurs in nature as monetite; an intermediate in preparing hydroxyapatite | 1.98 | 1 | 0 | calcium phosphate | |
| calcium phosphate, monobasic, anhydrous calcium phosphate, monobasic: MW 234.05 | 1.98 | 1 | 0 | calcium phosphate | fertilizer |
| tricalcium phosphate tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues. | 2.37 | 2 | 0 | calcium phosphate | |
| hydroxymethanediphosphonic acid hydroxymethanediphosphonic acid: RN given refers to parent cpd | 1.96 | 1 | 0 | 1,1-bis(phosphonic acid) | |
| yttrium radioisotopes Yttrium Radioisotopes: Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes. | 3.35 | 1 | 1 | ||
| technetium tc 99m hydroxymethylene diphosphonate technetium Tc 99m hydroxymethylene diphosphonate: bone-seeking radiopharmaceutical | 4.31 | 6 | 0 | ||
| technetium tc 99m n-(methylamino)methylene diphosphonate technetium Tc 99m N-(methylamino)methylene diphosphonate: structure given in first source | 1.96 | 1 | 0 | ||
| calcium pyrophosphate [no description available] | 1.98 | 1 | 0 | ||
| technetium tc 99m pentetate Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents. | 2.36 | 2 | 0 | ||
| tibolone tibolone: used in prevention of postmenopausal osteoporosis. tibolone : Estran-3-one with a double bond between positions 5 and 10, and bearing both an ethynyl group and a hydroxy group at position 17 (R-configuration). A synthetic steroid hormone drug which acts as an agonist at all five type I steroid hormone receptors, it is used in the prevention of postmenopausal osteoporosis and for treatment of endometriosis. | 1.96 | 1 | 0 | 17beta-hydroxy steroid; terminal acetylenic compound | bone density conservation agent; hormone agonist |
| pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups. | 3.34 | 7 | 0 | diphosphate ion | |
| succimer Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning. | 1.96 | 1 | 0 | dicarboxylic acid; dithiol; sulfur-containing carboxylic acid | chelator |
| sodium borohydride sodium borohydride: RN given refers to parent cpd | 1.96 | 1 | 0 | inorganic sodium salt; metal tetrahydridoborate | |
| tin [no description available] | 3.06 | 5 | 0 | carbon group element atom; elemental tin; metal atom | micronutrient |
| strontium Strontium: An element of the alkaline earth family of metals. It has the atomic symbol Sr, atomic number 38, and atomic weight 87.62. | 3.35 | 1 | 1 | alkaline earth metal atom | |
| sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine. | 2.36 | 2 | 0 | chalcogen; nonmetal atom | macronutrient |
| strontium radioisotopes Strontium Radioisotopes: Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes. | 3.75 | 2 | 1 | ||
| technetium tc 99m pyrophosphate Technetium Tc 99m Pyrophosphate: A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities. | 3.35 | 7 | 0 | ||
| technetium tc 99m diphosphonate technetium Tc 99m diphosphonate: bone seeking radiopharmaceutical whose concentration in bone depends upon regional blood flow & bone metabolism | 1.96 | 1 | 0 | ||
| sodium pertechnetate tc 99m Sodium Pertechnetate Tc 99m: A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints. | 1.98 | 1 | 0 | ||
| technetium tc 99m lidofenin Technetium Tc 99m Lidofenin: A nontoxic radiopharmaceutical that is used in RADIONUCLIDE IMAGING for the clinical evaluation of hepatobiliary disorders in humans. | 1.96 | 1 | 0 | ||
| technetium tc 99m sulfur colloid Technetium Tc 99m Sulfur Colloid: A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, liver, and spleen. | 2.36 | 2 | 0 | ||
| technetium tc 99m gluconate [no description available] | 2.65 | 3 | 0 | ||
| technetium tc 99m medronate Technetium Tc 99m Medronate: A gamma-emitting radionuclide imaging agent used primarily in skeletal scintigraphy. Because of its absorption by a variety of tumors, it is useful for the detection of neoplasms. | 5.86 | 32 | 0 |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Bone Cancer [description not available] | 0 | 5.3 | 13 | 1 |
| Cancer of Prostate [description not available] | 0 | 2.68 | 3 | 0 |
| Androgen-Independent Prostatic Cancer [description not available] | 0 | 2.25 | 1 | 0 |
| Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. | 0 | 5.3 | 13 | 1 |
| Prostatic Neoplasms Tumors or cancer of the PROSTATE. | 0 | 2.68 | 3 | 0 |
| Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE. | 0 | 2.25 | 1 | 0 |
| Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. | 0 | 2.15 | 1 | 0 |
| Calcification, Pathologic [description not available] | 0 | 3.57 | 3 | 0 |
| Chronic Kidney Failure [description not available] | 0 | 3.58 | 3 | 0 |
| Disease, Pulmonary [description not available] | 0 | 1.95 | 1 | 0 |
| Calcinosis Pathologic deposition of calcium salts in tissues. | 0 | 3.57 | 3 | 0 |
| Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. | 0 | 3.58 | 3 | 0 |
| Lung Diseases Pathological processes involving any part of the LUNG. | 0 | 1.95 | 1 | 0 |
| Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. | 0 | 2.37 | 2 | 0 |
| Basedow Disease [description not available] | 0 | 2.03 | 1 | 0 |
| Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). | 0 | 2.03 | 1 | 0 |
| Bone Diseases Diseases of BONES. | 0 | 3.98 | 5 | 0 |
| Carcinoma, Anaplastic [description not available] | 0 | 2.36 | 2 | 0 |
| Coronary Heart Disease [description not available] | 0 | 1.96 | 1 | 0 |
| Cardiac Failure [description not available] | 0 | 1.96 | 1 | 0 |
| Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer. | 0 | 2.36 | 2 | 0 |
| Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. | 0 | 1.96 | 1 | 0 |
| Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. | 0 | 1.96 | 1 | 0 |
| Metastase [description not available] | 0 | 1.96 | 1 | 0 |
| Sarcoma, Epithelioid [description not available] | 0 | 1.96 | 1 | 0 |
| Invasiveness, Neoplasm [description not available] | 0 | 1.96 | 1 | 0 |
| Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. | 0 | 1.96 | 1 | 0 |
| Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. | 0 | 1.96 | 1 | 0 |
| Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc. | 0 | 1.96 | 1 | 0 |
| Abdominal Neoplasms New abnormal growth of tissue in the ABDOMEN. | 0 | 1.96 | 1 | 0 |
| Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) | 0 | 1.96 | 1 | 0 |
| Thoracic Neoplasms New abnormal growth of tissue in the THORAX. | 0 | 1.96 | 1 | 0 |
| Low Bone Density [description not available] | 0 | 2.87 | 4 | 0 |
| Hyperthyroid [description not available] | 0 | 1.96 | 1 | 0 |
| Adult Rickets [description not available] | 0 | 2.36 | 2 | 0 |
| Age-Related Osteoporosis [description not available] | 0 | 3.29 | 2 | 0 |
| CKD-MBD [description not available] | 0 | 4.13 | 6 | 0 |
| Bone Diseases, Metabolic Diseases that affect the METABOLIC PROCESSES of BONE TISSUE. | 0 | 2.87 | 4 | 0 |
| Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. | 0 | 1.96 | 1 | 0 |
| Osteomalacia Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis. | 0 | 2.36 | 2 | 0 |
| Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. | 0 | 3.29 | 2 | 0 |
| Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. | 0 | 4.13 | 6 | 0 |
| Cardiovascular Stroke [description not available] | 0 | 2.65 | 3 | 0 |
| Acute Disease Disease having a short and relatively severe course. | 0 | 1.95 | 1 | 0 |
| Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). | 0 | 2.65 | 3 | 0 |
| Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES. | 0 | 2.36 | 2 | 0 |
| Cancer of the Thyroid [description not available] | 0 | 2.36 | 2 | 0 |
| Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. | 0 | 2.36 | 2 | 0 |
| Carcinoma, Oat Cell [description not available] | 0 | 1.96 | 1 | 0 |
| Adenocarcinoma, Basal Cell [description not available] | 0 | 4.04 | 3 | 1 |
| Carcinoma, Epidermoid [description not available] | 0 | 1.96 | 1 | 0 |
| Cancer of Lung [description not available] | 0 | 2.65 | 3 | 0 |
| Adenocarcinoma A malignant epithelial tumor with a glandular organization. | 0 | 4.04 | 3 | 1 |
| Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) | 0 | 1.96 | 1 | 0 |
| Lung Neoplasms Tumors or cancer of the LUNG. | 0 | 2.65 | 3 | 0 |
| Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7) | 0 | 1.96 | 1 | 0 |
| Foreign-Body Reaction Chronic inflammation and granuloma formation around irritating foreign bodies. | 0 | 1.96 | 1 | 0 |
| Polyarthritis [description not available] | 0 | 1.96 | 1 | 0 |
| Arthritis Acute or chronic inflammation of JOINTS. | 0 | 1.96 | 1 | 0 |
| Ewing Sarcoma [description not available] | 0 | 1.96 | 1 | 0 |
| Osteoid Osteoma [description not available] | 0 | 1.96 | 1 | 0 |
| Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA. | 0 | 2.37 | 2 | 0 |
| Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females. | 0 | 1.96 | 1 | 0 |
| Osseous Paget's Disease [description not available] | 0 | 3.06 | 5 | 0 |
| Osteitis Deformans A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry. | 0 | 3.06 | 5 | 0 |
| Rheumatoid Arthritis [description not available] | 0 | 1.96 | 1 | 0 |
| Plica Syndrome [description not available] | 0 | 1.96 | 1 | 0 |
| Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. | 0 | 1.96 | 1 | 0 |
| Synovitis Inflammation of the SYNOVIAL MEMBRANE. | 0 | 1.96 | 1 | 0 |
| Osteogenic Sarcoma [description not available] | 0 | 2.36 | 2 | 0 |
| Chondrosarcoma A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed) | 0 | 1.95 | 1 | 0 |
| Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) | 0 | 2.36 | 2 | 0 |
| Kahler Disease [description not available] | 0 | 1.95 | 1 | 0 |
| Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. | 0 | 1.95 | 1 | 0 |
| Hand-Schu00FCller-Christian Disease [description not available] | 0 | 1.96 | 1 | 0 |
| Histiocytosis, Langerhans-Cell A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder. | 0 | 1.96 | 1 | 0 |
| Giant Cell Tumors Tumors of bone tissue or synovial or other soft tissue characterized by the presence of giant cells. The most common are giant cell tumor of tendon sheath and GIANT CELL TUMOR OF BONE. | 0 | 1.96 | 1 | 0 |
| Infection [description not available] | 0 | 1.96 | 1 | 0 |
| Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases. | 0 | 1.96 | 1 | 0 |
| Aseptic Necrosis of Bone [description not available] | 0 | 3.29 | 2 | 0 |
| Osteonecrosis Death of a bone or part of a bone, either atraumatic or posttraumatic. | 0 | 3.29 | 2 | 0 |
| Cardiac Cancer [description not available] | 0 | 1.95 | 1 | 0 |
| Chylopericardium [description not available] | 0 | 1.95 | 1 | 0 |
| Pericardial Effusion Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE. | 0 | 1.95 | 1 | 0 |
| Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. | 0 | 1.96 | 1 | 0 |
| HbS Disease [description not available] | 0 | 1.96 | 1 | 0 |
| Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. | 0 | 1.96 | 1 | 0 |
| Cancer of Liver [description not available] | 0 | 1.96 | 1 | 0 |
| Cancer of Ovary [description not available] | 0 | 1.96 | 1 | 0 |
| Liver Neoplasms Tumors or cancer of the LIVER. | 0 | 1.96 | 1 | 0 |
| Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. | 0 | 1.96 | 1 | 0 |
| Thalassemias [description not available] | 0 | 1.96 | 1 | 0 |
| Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. | 0 | 1.96 | 1 | 0 |
| Clubbed Fingers [description not available] | 0 | 1.96 | 1 | 0 |
| Bone Fractures [description not available] | 0 | 4.46 | 5 | 0 |
| Kidney Diseases Pathological processes of the KIDNEY or its component tissues. | 0 | 2.37 | 2 | 0 |
| Fractures, Bone Breaks in bones. | 0 | 4.46 | 5 | 0 |
| Ache [description not available] | 0 | 1.96 | 1 | 0 |
| Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. | 0 | 1.96 | 1 | 0 |
| Colorectal Cancer [description not available] | 0 | 3.37 | 1 | 1 |
| Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. | 0 | 3.37 | 1 | 1 |
| Disease Exacerbation [description not available] | 0 | 2.91 | 1 | 0 |
| Recrudescence [description not available] | 0 | 2.91 | 1 | 0 |
| Factitious Disorders Disorders characterized by physical or psychological symptoms that are not real, genuine, or natural. | 0 | 2.91 | 1 | 0 |
| Algodystrophic Syndrome [description not available] | 0 | 4.07 | 3 | 0 |
| Reflex Sympathetic Dystrophy A syndrome characterized by severe burning pain in an extremity accompanied by sudomotor, vasomotor, and trophic changes in bone without an associated specific nerve injury. This condition is most often precipitated by trauma to soft tissue or nerve complexes. The skin over the affected region is usually erythematous and demonstrates hypersensitivity to tactile stimuli and erythema. (Adams et al., Principles of Neurology, 6th ed, p1360; Pain 1995 Oct;63(1):127-33) | 0 | 4.07 | 3 | 0 |
| ANS (Autonomic Nervous System) Diseases [description not available] | 0 | 2.91 | 1 | 0 |
| Bone Loss, Osteoclastic [description not available] | 0 | 2.91 | 1 | 0 |
| Bone Stress Reaction [description not available] | 0 | 2.91 | 1 | 0 |
| Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body. | 0 | 2.91 | 1 | 0 |
| Ankylosing Spondylarthritis [description not available] | 0 | 1.95 | 1 | 0 |
| Arthritis, Post-Infectious [description not available] | 0 | 1.95 | 1 | 0 |
| Spondylitis, Ankylosing A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions. | 0 | 1.95 | 1 | 0 |
| Arthritis, Reactive An aseptic, inflammatory arthritis developing secondary to a primary extra-articular infection, most typically of the GASTROINTESTINAL TRACT or UROGENITAL SYSTEM. The initiating trigger pathogens are usually SHIGELLA; SALMONELLA; YERSINIA; CAMPYLOBACTER; or CHLAMYDIA TRACHOMATIS. Reactive arthritis is strongly associated with HLA-B27 ANTIGEN. | 0 | 1.95 | 1 | 0 |
| Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. | 0 | 2.89 | 1 | 0 |
| Inferior Dislocation [description not available] | 0 | 1.97 | 1 | 0 |
| Injuries, Leg [description not available] | 0 | 1.97 | 1 | 0 |
| Spinal Diseases Diseases involving the SPINE. | 0 | 1.97 | 1 | 0 |
| Injuries, Spinal [description not available] | 0 | 1.97 | 1 | 0 |
| Spinal Neoplasms New abnormal growth of tissue in the SPINE. | 0 | 1.97 | 1 | 0 |
| Spondylitis Inflammation of the SPINE. This includes both arthritic and non-arthritic conditions. | 0 | 1.97 | 1 | 0 |
| Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed) | 0 | 1.96 | 1 | 0 |
| Breast Cancer [description not available] | 0 | 1.96 | 1 | 0 |
| Breast Neoplasms Tumors or cancer of the human BREAST. | 0 | 1.96 | 1 | 0 |
| Hypocalcemia Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed) | 0 | 1.97 | 1 | 0 |
| Pain, Intractable Persistent pain that is refractory to some or all forms of treatment. | 0 | 3.35 | 1 | 1 |
| Jaw Diseases Diseases involving the JAW. | 0 | 1.96 | 1 | 0 |